Which Upper Limit for Vitamin B6 Should Be Followed?
Follow the EFSA upper limit of 12 mg/day for adults, as it represents the most recent (2023) and rigorously derived safety threshold based on peripheral neuropathy risk. 1
The Evidence-Based Recommendation
The EFSA 2023 scientific opinion establishes a tolerable upper intake level (UL) of 12 mg/day for adults (including pregnant and lactating women), derived from systematic review of vitamin B6 toxicity data 1. This supersedes older recommendations and provides age-specific guidance:
Age-Specific EFSA Upper Limits:
- Infants (4-11 months): 2.2-2.5 mg/day
- Children (1-6 years): 3.2-4.5 mg/day
- Children/Adolescents (7-17 years): 6.1-10.7 mg/day
- Adults (≥18 years): 12 mg/day 1
Why EFSA Over IOM?
The IOM (Institute of Medicine) established ULs of 80-100 mg/day for adults 2, which are 8-fold higher than EFSA's recommendation. The critical difference lies in methodology and timing:
EFSA's 2023 analysis is superior because:
- Uses more recent systematic review methodology
- Identifies a reference point of 50 mg/day from case-control studies where peripheral neuropathy develops
- Applies an uncertainty factor of 4 to account for the inverse dose-time relationship (higher doses cause faster symptom onset)
- Incorporates vigilance data and case reports showing toxicity at doses as low as 24-40 mg/day 3
- Validates findings with animal data (LOAEL of 50 mg/kg bw/day in dogs, yielding similar UL of 11.7 mg/day) 1
The IOM values are outdated and fail to account for accumulating evidence of neurotoxicity at lower chronic doses.
Clinical Rationale: Peripheral Neuropathy Risk
Peripheral neuropathy is the critical effect for establishing the UL 1. The relationship between excess vitamin B6 and neuropathy is well-established, with symptoms including:
- Sensory nerve dysfunction
- Ataxia
- Paresthesias
Key clinical pitfall: Neuropathy can develop at doses previously considered "safe" (100-300 mg/day) when taken chronically 3. The EFSA approach accounts for this by using a lower reference point and appropriate uncertainty factors.
Practical Implementation
For clinical practice:
- Therapeutic dosing: 4-6 mg/day for parenteral nutrition 2
- Enteral nutrition: At least 1.5 mg/day (when providing 1500 kcal) 2
- Supplement users: Most at risk of exceeding UL; counsel to stay below 12 mg/day 1
- Washout period: 20-40 days required for complete clearance if toxicity suspected 4
Monitoring considerations:
- Plasma pyridoxal 5-phosphate (PLP) levels correlate with intake and body stores 2
- Elevated PLP-to-PL ratios may indicate excessive intake 5
- Remain alert for unexplained neuropathy in patients taking supplements 3
Population Safety
Based on current intake data, EU populations are unlikely to exceed the 12 mg/day UL from diet alone, except for regular users of high-dose food supplements 1. This provides an adequate safety margin while protecting against neurotoxicity risk.
The EFSA 12 mg/day UL represents the most scientifically rigorous, recent, and clinically protective standard for vitamin B6 safety.